Drug costs in the management of metastatic castration-resistant prostate cancer in Canada
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1472-6963
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Drug costs in the management of metastatic castration-resistant prostate cancer in Canada ; volume:14 ; number:1 ; day:13 ; month:6 ; year:2014 ; pages:1-14 ; date:12.2014
BMC health services research ; 14, Heft 1 (13.6.2014), 1-14, 12.2014
- Creator
-
Dragomir, Alice
- Contributor
-
Dinea, Daniela
Vanhuyse, Marie
Cury, Fabio L.
Aprikian, Armen G.
SpringerLink (Online service)
- DOI
-
10.1186/1472-6963-14-252
- URN
-
urn:nbn:de:1111-2016072151373
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Dragomir, Alice
- Dinea, Daniela
- Vanhuyse, Marie
- Cury, Fabio L.
- Aprikian, Armen G.
- SpringerLink (Online service)
Other Objects (12)
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Healthcare Costs for Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone or Enzalutamide
Ureter metastatic castration-resistant prostate cancer: a case report
Physician preferences for non-metastatic castration-resistant prostate cancer treatment
Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Treatment-Related Healthcare Costs of Metastatic Castration-Resistant Prostate Cancer in Germany: A Claims Data Study
Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer
Metastatic Castration-Resistant Prostate Cancer: Advances in Treatment and Symptom Management
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer
Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey
Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer